What is ABS?
ABS Bio operates as a comprehensive biotechnology services provider, specializing in critical areas such as biospecimen sourcing, advanced cell culture techniques, meticulous biobanking, and essential laboratory support. The company serves as a vital extension of its clients' research laboratories, primarily focusing on pharmaceutical and biotech entities. By supplying high-quality biological materials and sophisticated processing services, ABS Bio plays a crucial role in accelerating the complex processes of drug discovery and preclinical research, thereby enhancing the efficiency and success rates of its partners' development pipelines.
How much funding has ABS raised?
ABS has raised a total of $350K across 1 funding round:
Debt
$350K
Debt (2020): $350K with participation from PPP
Key Investors in ABS
PPP
Public-Private Partnership
What's next for ABS?
With its recent large-scale late-stage funding, ABS is poised for significant expansion and operational enhancement. This capital infusion is expected to fuel advancements in its service offerings, potentially including the adoption of new technologies for biospecimen processing and biobanking, as well as scaling its laboratory support capabilities. The company's strategic focus will likely involve deepening its partnerships within the pharmaceutical and biotech industries, aiming to become an indispensable resource for drug discovery and preclinical research. Continued investment in quality control and regulatory compliance will be paramount to maintaining its reputation and securing future growth opportunities in the dynamic life sciences market.
See full ABS company page
